Prevents organ rejection in kidney, liver, and heart allogeneic transplants. ANDA 219049, held by Qilu. Cyclosporine.
As of Nov 16, 2026, ANDA 219049 (Cyclosporine), held by Qilu, was first approved by FDA on Sep 15, 2025, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 15, 2025 | Original application | Approved | None posted |
| Cyclosporine25MG · capsule;oral | Cyclosporine | Rx |
| Cyclosporine100MG · capsule;oral | Cyclosporine | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters